A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Dabrafenib (Primary)
- Indications Brain metastases; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 16 Jan 2018 Planned End Date changed from 27 May 2019 to 2 Jul 2019.
- 16 Jan 2018 Planned primary completion date changed from 27 May 2019 to 9 Jan 2019.
- 30 Oct 2017 Planned End Date changed from 17 Jul 2018 to 27 May 2019.